share_log

Theriva Biologics | 10-Q: Q2 2024 Earnings Report

Theriva Biologics | 10-Q: Q2 2024 Earnings Report

Theriva Biologics | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/13 20:22

Moomoo AI 已提取核心信息

Theriva Biologics reported a net loss of $8.3 million ($0.43 per share) for Q2 2024, compared to a $5.1 million loss ($0.34 per share) in Q2 2023. Revenue remained minimal while R&D expenses were $3.0 million and G&A expenses decreased to $1.5 million. The company recorded a $4.0 million goodwill impairment charge during the quarter.The company's lead candidate VCN-01 continues to advance in clinical trials, with patient enrollment ongoing in the Phase 2 VIRAGE trial for pancreatic cancer. Positive topline data was reported from a Phase 1 trial of intravitreal VCN-01 in retinoblastoma patients. The FDA granted Fast Track Designation for VCN-01 in combination with chemotherapy for pancreatic cancer.With cash and equivalents of $16.6 million as of June 30, 2024, management expects current funding to support operations into Q2 2025. However, the company will require additional capital to advance later-stage clinical trials and commercialization efforts. During Q2, Theriva raised $1.8 million through an at-the-market offering of 4.4 million shares.
Theriva Biologics reported a net loss of $8.3 million ($0.43 per share) for Q2 2024, compared to a $5.1 million loss ($0.34 per share) in Q2 2023. Revenue remained minimal while R&D expenses were $3.0 million and G&A expenses decreased to $1.5 million. The company recorded a $4.0 million goodwill impairment charge during the quarter.The company's lead candidate VCN-01 continues to advance in clinical trials, with patient enrollment ongoing in the Phase 2 VIRAGE trial for pancreatic cancer. Positive topline data was reported from a Phase 1 trial of intravitreal VCN-01 in retinoblastoma patients. The FDA granted Fast Track Designation for VCN-01 in combination with chemotherapy for pancreatic cancer.With cash and equivalents of $16.6 million as of June 30, 2024, management expects current funding to support operations into Q2 2025. However, the company will require additional capital to advance later-stage clinical trials and commercialization efforts. During Q2, Theriva raised $1.8 million through an at-the-market offering of 4.4 million shares.
Theriva生物制品报告2024年第二季度净亏损830万美元（每股0.43美元），相比之下，2023年第二季度亏损510万美元（每股0.34美元）。营业收入保持微不足道，而研发费用为300万美元，管理费用减少至150万美元。公司在本季度记录了400万美元的商誉减值损失。公司主要候选药物VCN-01继续在临床试验中推进，第二阶段VIRAGE试验的 pancreatic癌患者正在招募中。第一阶段的视网膜母细胞瘤患者用VCN-01进行的玻璃体内注射试验报告了积极的顶线数据。FDA已授予VCN-01与化疗联合用于胰腺癌的快速通道认证。截至2024年6月30日，公司现金及现金等价物为1660万美元，管理层预计当前资金可支持运营至2025年第二季度。然而，公司将需要额外资金以推进后期临床试验和商业化工作。在第二季度，Theriva通过440万股的市场发行筹集了180万美元。
Theriva生物制品报告2024年第二季度净亏损830万美元（每股0.43美元），相比之下，2023年第二季度亏损510万美元（每股0.34美元）。营业收入保持微不足道，而研发费用为300万美元，管理费用减少至150万美元。公司在本季度记录了400万美元的商誉减值损失。公司主要候选药物VCN-01继续在临床试验中推进，第二阶段VIRAGE试验的 pancreatic癌患者正在招募中。第一阶段的视网膜母细胞瘤患者用VCN-01进行的玻璃体内注射试验报告了积极的顶线数据。FDA已授予VCN-01与化疗联合用于胰腺癌的快速通道认证。截至2024年6月30日，公司现金及现金等价物为1660万美元，管理层预计当前资金可支持运营至2025年第二季度。然而，公司将需要额外资金以推进后期临床试验和商业化工作。在第二季度，Theriva通过440万股的市场发行筹集了180万美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    特斯拉绩后巨震，后市你怎么看？
    特斯拉2024年Q4营收257.1亿美元，同比增长2%，不及预期。Cybercab计划2026年投产，预计车辆业务将于2025年恢复增长。面对特朗普回归，特斯拉股价能否在2025年继续攀升？ 展开
    TSLA财报预告：通过猜测开盘价来获取奖励！